Featured 13F manager
Palo Alto Investors LP Palo Alto Investors
Palo Alto, CA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $724M
- 52 Positions
- 2026 Q2
- +10.7% QoQ
- Top 5 37.7%
Palo Alto Investors files Palo Alto Investors LP as a Form 13F. The latest book is 2026 Q2 at $724M, up 10.7% QoQ, led by Ptc Therapeutics, Acadia Pharmaceuticals, and Insmed.
Portfolio
top 5 37.7% · top 10 61.3%
- PTC - Ptc Therapeutics 10.4%
- ACAD - Acadia Pharmaceuticals 10.0%
- INSM - Insmed 6.1%
- MIRM - Mirum Pharmaceuticals 5.6%
- ANAB - Anaptysbio 5.6%
- BMRN - Biomarin Pharmaceutical 5.4%
- DYN - Dyne Therapeutics 5.1%
- UTHR - United Therapeutics 4.7%
- IRON - Disc Medicine 4.2%
- BIIB - Biogen 4.2%
- IOVA - Iovance Biotherapeutics 3.0%
- RARE — 2.8%
- Other 32.9%
AUM over time
Book
| INSM - Insmed | 17.15% | Reduce −17.4% | 1,603,465 | $69.04 | $111M | −337,528 | −$31M |
| FOLD - Amicus | 11.18% | Reduce −5.9% | 7,662,479 | $9.42 | $72M | −482,832 | −$15M |
| BMRN - Biomarin Pharmaceutical | 10.87% | Reduce −2.1% | 1,067,266 | $65.73 | $70M | −22,790 | −$6M |
| UTHR - United Therapeutics | 8.51% | Reduce −15.0% | 155,714 | $352.84 | $55M | −27,532 | −$11M |
| ACAD - Acadia Pharmaceuticals | 7.82% | Add +8.9% | 2,748,599 | $18.35 | $50M | +224,643 | +$12M |
| ALNY - Alnylam Pharmaceuticals | 5.13% | Hold | 140,681 | $235.31 | $33M | — | — |
| BIIB - Biogen | 4.51% | Reduce −16.9% | 190,148 | $152.92 | $29M | −38,768 | −$15M |
| Sarepta Therapeutics | 3.96% | Hold | 210,258 | $121.59 | $26M | — | — |
| NVCR - Novocure | 3.76% | Add +37.2% | 814,191 | $29.80 | $24M | +220,651 | +$15M |
| PRTA - Prothena | 3.73% | Hold | 1,737,964 | $13.85 | $24M | — | — |
| IOVA - Iovance Biotherapeutics | 3.49% | Hold | 3,041,685 | $7.40 | $23M | — | — |
| EHTH - Ehealth | 2.74% | Reduce −20.0% | 1,878,127 | $9.40 | $18M | −469,392 | +$8M |
| PTC - Ptc Therapeutics | 2.70% | Add +46.1% | 386,413 | $45.14 | $17M | +121,944 | +$8M |
| Staar Surgical | 1.88% | Reduce −54.1% | 500,775 | $24.29 | $12M | −590,833 | −$28M |
| ANAB - Anaptysbio | 1.73% | Hold | 843,971 | $13.24 | $11M | — | — |
| ALKS - Alkermes | 1.29% | Reduce −24.8% | 289,308 | $28.76 | $8M | −95,348 | −$2M |
| ALGN - Align Technology | 1.22% | Hold | 37,772 | $208.51 | $8M | — | — |
| Gossamer Bio | 0.88% | Hold | 6,277,093 | $0.9046 | $6M | — | — |
| Acelyrin | 0.87% | Hold | 1,792,895 | $3.14 | $6M | — | — |
| SNDX - Syndax Pharmaceuticals | 0.83% | Hold | 405,193 | $13.22 | $5M | — | — |
| BCYC — | 0.54% | Add +317.8% | 248,934 | $14.00 | $3M | +189,352 | +$2M |
| Karyopharm Therapeutics | 0.51% | Reduce −3.8% | 4,907,001 | $0.6763 | $3M | −195,192 | −$916K |
| Verve Therapeutics | 0.50% | Hold | 575,817 | $5.64 | $3M | — | — |
| EW - Edwards Lifesciences | 0.45% | Hold | 39,473 | $74.03 | $3M | — | — |
| BNTX - Biontech Se- | 0.45% | Hold | 25,206 | $113.95 | $3M | — | — |
| Nevro | 0.43% | Hold | 750,371 | $3.72 | $3M | — | — |
| MIRM - Mirum Pharmaceuticals | 0.41% | Hold | 64,700 | $41.35 | $3M | — | — |
| NUVB - Nuvation Bio · CL A | 0.32% | Hold | 772,652 | $2.66 | $2M | — | — |
| TVTX - Travere Therapeutics | 0.30% | Hold | 110,719 | $17.42 | $2M | — | — |
| PYXS - Pyxis Oncology | 0.25% | Add +510.2% | 1,037,421 | $1.56 | $2M | +867,421 | +$994K |
| Vyne Therapeutics Pipe | 0.23% | Hold | 445,434 | $3.35 | $1M | — | — |
| ACRS - Aclaris Therapeutics | 0.22% | Hold | 569,832 | $2.48 | $1M | — | — |
| TSHA - Taysha Gene Therapies | 0.22% | Hold | 811,268 | $1.73 | $1M | — | — |
| STOK - Stoke Therapeutics | 0.22% | Hold | 125,861 | $11.03 | $1M | — | — |
| ALDX - Aldeyra Therapeutics | 0.17% | Hold | 225,465 | $4.99 | $1M | — | — |
| HUM - Humana | 0.16% | Hold | 3,985 | $253.71 | $1M | — | — |
| Jasper Therapeutics | 0.10% | New | 30,651 | $21.38 | $655K | +30,651 | +$655K |
| ABEO - Abeona Therapeutics | 0.09% | Add +746.2% | 108,865 | $5.57 | $606K | +96,000 | +$525K |
| URGN - Urogen Pharma | 0.04% | Hold | 24,500 | $10.65 | $261K | — | — |
| RLMD - Relmada Therapeutics | 0.04% | Reduce −32.4% | 495,146 | $0.5200 | $257K | −237,254 | −$2M |
| Instil Bio | 0.03% | Hold | 11,165 | $19.09 | $213K | — | — |
| Akari Therapeutics - | 0.03% | New | 146,024 | $1.22 | $178K | +146,024 | +$178K |
| Generation Bio | 0.02% | Hold | 150,475 | $1.06 | $160K | — | — |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2024 Q3
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Revance Therapeutics | 1.09% | Exit | 0 | $5.19 | $8M | −1,611,787 | −$8M |
| Sage Therapeutics | 0.95% | Exit | 0 | $7.22 | $7M | −1,010,833 | −$7M |
| Elevation Oncology | 0.10% | Exit | 0 | $0.6001 | $779K | −1,298,097 | −$779K |
| Bluebird Bio | 0.04% | Exit | 0 | $0.5196 | $314K | −604,260 | −$314K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 52 | $724M | +10.7% | RESTATEMENT | 8/19/2026 | 000207367926000102 |
| 2026 Q2 | 52 | $724M | — | RESTATEMENT | 8/18/2026 | 000207367926000101 |
| 2026 Q2 | 52 | $724M | — | 13F-HR | 8/17/2026 | 000207367926000096 |
| 2026 Q1 | 51 | $654M | −8.9% | 13F-HR | 5/15/2026 | 000130692326000004 |
| 2025 Q4 | 49 | $718M | +33.0% | 13F-HR | 2/17/2026 | 000130692326000002 |
| 2025 Q3 | 44 | $540M | +14.9% | 13F-HR | 11/14/2025 | 000130692325000019 |
| 2025 Q2 | 45 | $470M | −10.5% | 13F-HR | 8/14/2025 | 000130692325000016 |
| 2025 Q1 | 44 | $525M | −18.6% | 13F-HR | 5/15/2025 | 000130692325000014 |
| 2024 Q4 | 43 | $645M | −16.2% | 13F-HR | 2/14/2025 | 000130692325000010 |
| 2024 Q3 | 45 | $770M | −10.8% | 13F-HR | 11/14/2024 | 000130692324000012 |
| 2024 Q2 | 39 | $863M | −2.7% | 13F-HR | 8/14/2024 | 000130692324000010 |
| 2024 Q1 | 38 | $887M | −19.9% | 13F-HR | 5/15/2024 | 000130692324000008 |
| 2023 Q4 | 34 | $1.1B | — | RESTATEMENT | 2/15/2024 | 000130692324000007 |
| 2023 Q4 | 34 | $1.1B | +4.7% | 13F-HR | 2/14/2024 | 000130692324000002 |
| 2023 Q3 | 29 | $1.1B | −14.6% | 13F-HR | 11/14/2023 | 000130692323000014 |
| 2023 Q2 | 30 | $1.2B | +2.6% | 13F-HR | 8/14/2023 | 000130692323000012 |
| 2023 Q1 | 30 | $1.2B | +2.9% | 13F-HR | 5/15/2023 | 000130692323000011 |
| 2022 Q4 | 29 | $1.2B | −7.3% | 13F-HR | 2/14/2023 | 000130692323000009 |
| 2022 Q3 | 32 | $1.3B | +10.3% | 13F-HR | 11/14/2022 | 000130692322000016 |
| 2022 Q2 | 33 | $1.1B | −11.3% | 13F-HR | 8/15/2022 | 000130692322000015 |
| 2022 Q1 | 35 | $1.3B | −17.4% | 13F-HR | 5/16/2022 | 000130692322000014 |
| 2021 Q4 | 37 | $1.6B | −5.6% | 13F-HR | 2/14/2022 | 000130692322000004 |
| 2021 Q3 | 42 | $1.7B | — | 13F-HR | 11/15/2021 | 000130692321000026 |
About
Palo Alto Investors LP
23 processed 13Fs on this site · 2021 Q3–2026 Q2